甲基胺通过LIPH/LPA/PI3K/AKT信号轴调节微质极化和糖解活性,促进帕金森病的发生
Yanghong Zou1, Chunhai Zhang2, Hui Bian3
1The Second Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China; NHC Key Lab of Drug Addiction Medicine (Kunming Medical University), Kunming 650500, Yunnan, China.
International immunopharmacology
|February 2, 2026
概括
甲基胺 (METH) 滥用促进帕金森病 (PD) 的进展,通过通过LIPH/LPA/PI3K/AKT通路激活微质M1极化和糖解. 这种机制加剧神经炎症和神经元损伤在PD.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 滥用甲基胺 (METH) 与增加帕金森病 (PD) 风险有关.
- 微质极化和改变的葡萄糖代谢是PD进展的关键因素.
研究的目的:
- 阐明METH促进PD进展的分子机制.
- 研究METH在调节微质极化和糖解中的作用.
主要方法:
- 在C57BL/6小鼠和BV2细胞中建立了METH诱导的PD模型.
- 评估了行为变化,神经元损伤,微质极化标记物,炎症性细胞因子和糖溶性活动.
- 使用了免疫光学,ELISA,西部涂抹和CCK-8测定.
主要成果:
- 在小鼠中,METH治疗恶化了PD类行为和 substantia nigra神经元损伤.
- METH诱导了M1微质极化,增加了促炎细胞因子 (TNF-α,IL-1β,IL-6),同时降低了M2标记物.
- 甲增强了微质糖解活性,并激活了LIPH/LPA/PI3K/AKT信号通路.
结论:
- METH促进了M1微质的两极分化和糖解活性.
- 在LIPH/LPA/PI3K/AKT信号通路中介METH的亲PD效应.
- 针对这种途径可能为METH相关的PD提供治疗策略.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28


